Renaissance Technologies
ADMA icon

Renaissance Technologies’s ADMA Biologics ADMA Stock Holding History

Renaissance Technologies’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.46M Sell
652,530
-610,104
-48% -$5.56M 0.01% 1411
2026
Q1 		$11.4M Sell
1,262,634
-269,987
-18% -$4.26M 0.02% 911
2025
Q4 		$28M Sell
1,532,621
-1,237,821
-45% -$20.9M 0.04% 475
2025
Q3 		$40.6M Sell
2,770,442
-375,611
-12% -$6.44M 0.05% 428
2025
Q2 		$57.3M Sell
3,146,053
-402,935
-11% -$8.22M 0.08% 292
2025
Q1 		$70.4M Sell
3,548,988
-220,900
-6% -$3.82M 0.11% 231
2024
Q4 		$64.7M Buy
3,769,888
+102,692
+3% +$1.93M 0.1% 244
2024
Q3 		$73.3M Buy
3,667,196
+1,085,061
+42% +$16.9M 0.11% 217
2024
Q2 		$28.9M Buy
2,582,135
+575,100
+29% +$4.82M 0.05% 453
2024
Q1 		$13.2M Buy
2,007,035
+949,100
+90% +$5.19M 0.02% 846
2023
Q4 		$4.78M Sell
1,057,935
-338,620
-24% -$1.25M 0.01% 1380
2023
Q3 		$5M Buy
1,396,555
+182,820
+15% +$704K 0.01% 1315
2023
Q2 		$4.48M Buy
1,213,735
+240,500
+25% +$891K 0.01% 1484
2023
Q1 		$3.22M Buy
973,235
+277,300
+40% +$959K ﹤0.01% 1735
2022
Q4 		$2.7M Buy
695,935
+57,535
+9% +$177K ﹤0.01% 1894
2022
Q3 		$1.55M Sell
638,400
-87,100
-12% -$209K ﹤0.01% 2202
2022
Q2 		$1.44M Buy
725,500
+198,800
+38% +$391K ﹤0.01% 2446
2022
Q1 		$964K Buy
526,700
+177,800
+51% +$277K ﹤0.01% 2748
2021
Q4 		$492K Buy
348,900
+113,900
+48% +$150K ﹤0.01% 3082
2021
Q3 		$266K Buy
235,000
+59,374
+34% +$83.2K ﹤0.01% 3117
2021
Q2 		$281K Buy
+175,626
New +$309K ﹤0.01% 3166
2018
Q4 		– Sell
-188,300
Closed -$1.17M – 3349
2018
Q3 		$1.17M Buy
188,300
+159,100
+545% +$916K ﹤0.01% 2538
2018
Q2 		$132K Buy
+29,200
New +$146K ﹤0.01% 3121
2017
Q4 		– Sell
-20,300
Closed -$63K – 3307
2017
Q3 		$63K Buy
20,300
+9,000
+80% +$30K ﹤0.01% 3117
2017
Q2 		$42K Buy
+11,300
New +$45.4K ﹤0.01% 3131

Other funds holding ADMA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies's ADMA Position: Q2 2026 in Review

Renaissance Technologies reduced its ADMA Biologics (ADMA) stake by 48% in Q2 2026, selling an estimated $5.56M and leaving 652,530 shares worth $5.46M. The position accounts for 0.01% of the portfolio, ranked #1411.

Renaissance Technologies first reported a position in ADMA in Q2 2017 and has held it in 25 quarters since. The position peaked at $73.3M in Q3 2024. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

  • Renaissance Technologies held 652,530 shares of ADMA Biologics worth $5.46M as of Q2 2026.
  • Renaissance Technologies sold 610,104 ADMA Biologics shares in Q2 2026, an estimated $5.56M.
  • ADMA Biologics made up 0.01% of Renaissance Technologies's portfolio in Q2 2026, its #1411 holding.
  • Renaissance Technologies first reported a position in ADMA Biologics in Q2 2017 and has held it in 25 quarters since.
  • Renaissance Technologies's ADMA Biologics position peaked at $73.3M in Q3 2024.
  • 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.